spacer
home > pmps > summer 2002 > mes or mess? - the creation of management information and the effective use of production data in pharmaceutical manufacturing
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

MES or Mess? - The Creation of Management Information and the Effective Use of Production Data in Pharmaceutical Manufacturing

As a participant in the IT industry and one that has implemented a wide variety of production information systems in several industries, I have seen all too many buzzwords come and go. The name of the game today is management execution systems (MES). According to the hype, MES delivers totally integrated information systems from the production line to the boardroom - a thrilling thought! This article will look at the different areas that are involved in MES and analyse the different data and information needs from the various participants in the production, delivery and decision processes.

Although Table 1 is not exhaustive - neither when it comes to describing the needs of each and every role, nor all the possible roles involved in the production process - it is sufficient for the purpose of analysing the various aspects of an MES system and the fundamental differences in information needs throughout the information chain.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Espen Gisvold, Managing Director of ESGH Espen Gisvold is the Managing Director of ESGH. He graduated from the University of Oslo, Norway in 1985 in Mathematics, Physics and Informatics and gained a Bachelor's degree in Informatics, which focused on numerical analysis.
Subsequently, Espen spent 10 years working with Saga Petroleum ASA, where he subsequently established and was responsible for the production information management system for the operations division. In 1996, Espen joined Inenco - a software house specialising in MES systems - as Product Quality Manager. In May 2000, he moved to Agilent Technologies as Test Lead Engineer.

spacer
Espen Gisvold
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was 271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement